

Table 1: (B cell Report Table 22): Percent of IgG+ B cells that are epitope-specific (KO-GT8++) magnitude testing between FNA samples (Wk03 (V05) vs. Wk 11(V09)) for the treatment group. Testing was done using Wilcoxon signed-rank test for paired data (two-sided, $\alpha = 0.05$) and p values less than 0.05 are highlighted.

Comparison	Dose	Number of Pairs	Median (Range)	P Value
Wk3 (V05) vs. Wk11 (V09)	20 μ g	7	18.7170 [4.7698, 50.8186] vs. 26.4226 [0.1418, 47.0750]	0.6875
	100 μ g	8	5.5505 [1.4178, 22.0344] vs. 1.2268 [0.1227, 4.0690]	0.0234